CHUGAI PHARMACEUTICAL CO., LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,852 JPY | -0.16% |
|
-1.40% | -9.17% |
| Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
| Apr. 24 | Chugai Pharmaceutical's Profit Slightly Up in Q1 | MT |
| Sales 2024 * | 1,092B 6.97B | Sales 2025 * | 1,136B 7.25B | Capitalization | 7,996B 51B |
|---|---|---|---|---|---|
| Net income 2024 * | 345B 2.2B | Net income 2025 * | 367B 2.34B | EV / Sales 2024 * | 6.51 x |
| Net cash position 2024 * | 881B 5.62B | Net cash position 2025 * | 1,003B 6.4B | EV / Sales 2025 * | 6.16 x |
| P/E ratio 2024 * |
23.2
x | P/E ratio 2025 * |
21.8
x | Employees | 7,604 |
| Yield 2024 * |
1.74% | Yield 2025 * |
1.84% | Free-Float | 38.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on Chugai Pharmaceutical Co., Ltd
More recommendations
More press releases
| 1 day | -0.16% | ||
| 1 week | -1.40% | ||
| Current month | -15.97% | ||
| 1 month | -18.30% | ||
| 3 months | -10.41% | ||
| 6 months | +12.18% | ||
| Current year | -9.17% |
1 week
4 726.00
5 376.00
1 month
4 726.005 985.00
Current year
4 726.006 697.00
1 year
3 380.006 697.00
3 years
3 191.006 697.00
5 years
2 290.006 697.00
10 years
853.676 697.00
| Managers | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 61 | 87-03-31 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Hisafumi Okabe
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Masayuki Oku
BRD | Director/Board Member | 79 | 15-02-28 |
Motoo Ueno
BRD | Director/Board Member | 66 | 84-03-31 |
James H. Sabry
BRD | Director/Board Member | 65 | 19-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.57% | 15 M€ | +7.34% | ||
| 1.87% | 60 M€ | +14.42% | ||
| 1.59% | 4 M€ | +13.95% | ||
| 1.53% | 67,864 M€ | +14.28% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4,852 | -0.16% | 4 608 300 |
| 24-04-25 | 4,860 | -5.65% | 3,680,700 |
| 24-04-24 | 5,151 | -0.66% | 3,109,900 |
| 24-04-23 | 5,185 | +0.68% | 2,322,000 |
| 24-04-22 | 5,150 | +4.65% | 2,610,900 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%).
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
4,860
JPY
Average target price
6,044
JPY
Spread / Average Target
+24.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.17% | 51.41B | |
| +24.74% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +5.63% | 201B | |
| -10.22% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 4519 Stock
